AC
KTTA icon

Armistice Capital’s Pasithea Therapeutics KTTA Stock Holding History

Armistice Capital’s Portfolio KTTA Stock Details KTTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-61,000
Closed -$192K – 262
2024
Q4 		$192K Buy
+61,000
New +$216K ﹤0.01% 194

Other funds holding KTTA

AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HC
Hurley Capital New York $187M AUM 23.24% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Armistice Capital's KTTA Position: Q1 2025 in Review

Armistice Capital sold out of Pasithea Therapeutics (KTTA) in Q1 2025, closing a stake of 61,000 shares — an estimated $192K sold.

Armistice Capital first reported a position in KTTA in Q4 2024 and held it in 1 quarter. The position peaked at $192K in Q4 2024. 8 funds tracked by Wall St. Rank hold KTTA as of Q1 2025.

  • Armistice Capital reported no remaining Pasithea Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Armistice Capital sold 61,000 Pasithea Therapeutics shares in Q1 2025, an estimated $192K.
  • Armistice Capital first reported a position in Pasithea Therapeutics in Q4 2024 and held it in 1 quarter.
  • Armistice Capital's Pasithea Therapeutics position peaked at $192K in Q4 2024.
  • 8 funds tracked by Wall St. Rank held Pasithea Therapeutics as of Q1 2025.

Based on Armistice Capital's 13F filing for Q1 2025, filed 15 May 2025.